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ABSTRACT:  
Background: Regional cerebral hypoperfusion is characteristic of Alzheimer’s disease (AD). 
Previous studies report conflicting findings in cognitively-normal individuals at high risk of 
AD. Understanding early preclinical perfusion alterations may improve understanding of AD 
pathogenesis and lead to new biomarkers and treatment targets. 
 
Methods: 3T arterial spin labelling MRI scans from 162 participants in the PREVENT-
Dementia cohort were analysed (cognitively normal participants aged 40-59, stratified by 
future dementia risk). Cerebral perfusion was compared vertex-wise according to APOE e4 
status and family history (FH). Correlations between individual perfusion, age and cognitive 
scores (COGNITO battery) were explored.  
 
Results: Regional hyperperfusion was found in APOE e4+ group (left cingulate and lateral 
frontal and parietal regions p<.01, TFCE) and in FH+ group (left temporal and parietal 
regions p<.01, TFCE). Perfusion did not correlate with cognitive test scores. 
 
Conclusions: Regional cerebral hyperperfusion in individuals at increased risk of AD in mid-
life may be a very early marker of functional brain change related to AD. Increased perfusion 
may reflect a functional ‘compensation’ mechanism, offsetting the effects of early neural 
damage, or may itself be risk factor for accelerating spread of degenerative pathology. 
 
Key words: Alzheimer’s disease, APOE e4, Family history, Magnetic Resonance Imaging 
(MRI), Arterial Spin Labelling (ASL), Cerebral Blood Flow (CBF), Cerebral hyperperfusion 
  
BACKGROUND: 
Some changes in the brain, such as increased amyloid deposition, precede cognitive changes 
in Alzheimer’s disease (AD) by years or decades and early identification of such changes 
may allow treatments to be targeted towards this early stage before gross brain damage 
occurs[1]. Brain function may also differ in at-risk individuals prior to any clinically 
identifiable deterioration in cognition or behaviour and could potentially further elucidate the 
natural history of the disease or be used to identify or predict conversion to a disease state. 
While these early changes are becoming well established for amyloid, they are less clear for 
other changes, especially functional changes such as blood flow. Though studies of familial 
AD indicate functional neuroimaging may be useful in this regard, more evidence is needed 
in sporadic late onset AD[2]. 
 
Arterial spin labelling (ASL) MRI is a non-invasive perfusion imaging technique for the 
measurement of cerebral blood flow (CBF). A radio frequency (RF) pulse is used to invert 
the magnetisation of water protons in a slab typically situated at the level of the carotids. 
After a short delay, sufficient to allow the ‘labelled’ blood to reach tissues of interest in the 
brain, a ‘tag’ image is acquired. This is subtracted from a ‘control’ image resulting in an 
image showing tissue perfusion[3]. Patterns of CBF produced with ASL have been shown to 
agree closely with those from perfusion single-photon emission computed tomography 
(SPECT) and metabolic positron emission tomography (PET) in healthy controls and patient 
groups[4,5]. SPECT and PET are well-established AD imaging markers and FDG-PET is 
included in the most recent diagnostic criteria for AD[6]. An established pattern of perfusion 
deficits measured using ASL is recognised in AD, with hypoperfusion most marked in the 
precuneus, posterior cingulate and superior parietal cortex and less prominently in the lateral 
frontal cortex, orbitofrontal cortex and temporal lobe structures including the hippocampus 
and parahippocampus[7].  
 
Relatively few studies have investigated differences in CBF between cognitively normal 
adults with and without risk factors for AD such as APOE e4 and family history (FH). 
Findings have been somewhat mixed; for example, Fleisher et al.[8] and Bangen et al.[9] 
found increased resting CBF in the medial temporal lobe in cognitively-normal participants 
who carried APOE e4. Wierenga et al.[10] found patterns of hypoperfusion similar to those in 
MCI and AD in cognitively normal older APOE e4 carriers but areas of hyperperfusion in 
younger APOE e4 carriers. However,  Chandler et al.[11] found reduced mean grey matter 
CBF in young APOE e4 carriers. In a larger study Okonkwo et al.[12] found no effect of 
APOE status on CBF but found that at mid-life those with a maternal FH of AD had 
perfusion deficits reminiscent of those seen in MCI and AD participants. Therefore, a 
consensus on the impacts of age, APOE e4 and FH has not yet been reached.  
 
CBF derived from ASL may be a promising functional candidate marker for AD as it has 
predictive value for cognitive decline and conversion from MCI to AD[13]. As ASL is non-
invasive and does not use ionising radiation there are evident advantages to using this tool in 
research and clinical populations, since scans can be repeated over time without carcinogenic 
risk. In order to address the limited and mixed evidence from the literature ASL data was 
collected from cognitively normal individuals in mid-life recruited as part of the PREVENT-
Dementia cohort. These individuals could be stratified for their risk of developing AD based 
on their family history and APOE allele carrier status. We hypothesised that changes in CBF 
would be seen in key regions of the brain in individuals at increased risk of developing AD 
and that such regions would include the cingulate gyrus and medial temporal lobe.  
 
 
  
METHODS: 
Participants: 210 cognitively normal men and women aged 40-59 years were recruited for 
the PREVENT-Dementia cohort[14] via a locally-held database of research volunteers[15] 
and underwent assessment with the aim of identifying AD biomarkers in cognitively normal 
individuals in mid-life. Assessment included a structured interview to elicit neuropsychiatric 
symptoms and to determine life-style factors. A computerised neuropsychometric battery 
(COGNITO) was administered[16]. Physical examination was performed and blood samples 
collected to determine APOE status. A Dementia Risk Score (DRS) was calculated for each 
participant. This validated score (from the CAIDE study[17]) includes age, gender, years of 
education, systolic blood pressure, BMI, serum cholesterol and level of physical activity. The 
18-point version incorporates APOE e4 allele carrier status, while the 15-point version does 
not; both forms of the scale were calculated. FH of dementia (defined as having at least one 
parent with a dementia diagnosis) was recorded. Of the 210 participants, 17 declined or had 
contraindications to MRI scanning, therefore 193 participants underwent scanning. 
 
Magnetic resonance imaging: 
Images were acquired using a Siemens Verio 3T MRI scanner. The following acquisitions 
were performed as part of a multi-modal MR examination: whole brain T1-weighted scan 
(MPRAGE, 160 slices, voxel size 1.0mm3, TR=2300ms, TE=2.98ms, FA=9o); ASL 
(PICORE Q2T, 50 pairs of control/ tag images, TR=2500ms, TE=11ms, inversion 
time=1800ms, bolus duration=700ms, voxel size 3.0x3.0x6.0mm, axial slices=14, slice 
gap=1.5mm, FA=90o). 
 
ASL scans were quality controlled by visual inspection, scans were excluded due to ASL-
related artefacts (e.g. fat saturation artefact and labelling asymmetry), brain abnormalities 
such as tumour, or if field of view (FOV) was inadequate. FOV was judged to be inadequate 
if any of the superior or posterior aspect was cropped or if cropping of the inferior aspect 
impinged on the hippocampus which was defined according to the Desikan-Killiany atlas. 
See figure 1 for scan inclusion/ exclusion pathway. ASL data from 162/193 (83.9%) 
individuals were available for analysis.  
 
 
Figure 1: scan inclusion/ exclusion pathway 
 
Image analysis ASL:  
Image post-processing was performed using FSL’s Bayesian Inference for ASL MRI 
(BASIL) toolbox[18] and the FreeSurfer image analysis suite (V6.0.0 
http://surfer.nmr.mgh.harvard.edu/). As part of the BASIL pipeline, the acquired ASL scans 
were motion corrected using FSL’s MCFLIRT and calibrated based on a proton density 
acquisition. CBF was quantified using the Buxton ASL kinetic model[19]. FreeSurfer was 
used to segment the individual T1 images into white and grey matter and CSF; individual 
ASL CBF maps were then co-registered to individual T1 images using a boundary-based 
registration algorithm[20] and projected onto the cortical ribbon. FreeSurfer uses surface-
based (rather than volume-based) registration and smoothing which has been shown in PET 
(with similar resolution to ASL) to improve signal to noise ratio (SNR), to reduce 
contamination of the grey matter signal with signal from white matter and cerebrospinal 
fluid[21] and to reduce mixing of grey matter signal originating from distinct cortical areas 
during the smoothing process[22]. The cortical ASL maps were smoothed with FWHM of 8. 
Regional CBF and regional cortical thickness values were extracted for each individual using 
FreeSurfer[23]. 
 
Statistical analysis: Alpha was set at 0.05 for all tests. Statistical analyses were performed 
using SPSS [IBM Corp. Released 2018. IBM SPSS Statistics for Macintosh, Version 25.0. 
Armonk, NY: IBM Corp.] and FSL[24]. Participants were grouped according to APOE e4 
allele carrier status and FH (both + vs -). Between group differences for age, gender, years of 
education, DRS score, FH (for the APOE groups), APOE status (for the FH groups), 
cognitive scores and mean cortical thickness were investigated. Age, years of education, DRS 
scores and cognitive test scores were found to have non-parametric distributions (normality 
tested using Shapiro-Wilk tests and Q-Q plots) and these nominal values were compared 
between groups using Mann-Whitney U test. The categorical values of gender  and APOE e4 
status were compared using Chi-squared tests.  
 
Regional CBF was compared between groups in a vertex-wise analysis using the Permutation 
Analysis of Linear Models (PALM) tool in FSL[25] with age, gender and years of education 
as covariates. This approach corrects for multiple comparisons (family-wise error correction 
(FWE)) in a data-driven manner using threshold-free cluster enhancement (TFCE) thus 
avoiding the inevitable arbitrary choices which must be made when applying vertex- and 
cluster-wise thresholds; this means that TFCE is also reported to be more sensitive to genuine 
group differences[26]. The FH group comparison was also made with the additional covariate 
of APOE status in order to explore the contribution of possible hereditary factors other than 
APOE e4. 
 
Relationships between CBF and age, years of education, DRS, cognitive test results and 
cortical thickness were assessed in the whole cohort in a vertex-wise correlation using 
PALM-FSL.  
 
  
RESULTS: 
Demographics: Groups were well-matched for age, gender and years of education (table 1). 
There was a trend towards a greater number of APOE e4 carriers in the FH+ group but this 
difference did not reach statistical significance. DRS was significantly higher in the APOE e4 
+ group than APOE e4 – group and in the  FH+ group than FH- group; the significant 
difference persisted for FH group but not APOE group when the contribution of APOE status 
to the DRS was removed (15-point DRS). The APOE e4+ group performed slightly better in 
the narrative recall task than the APOE e4- group; this was the only significant difference in 
cognitive test scores between groups. There was no difference in gross structural MR 
measures between groups, as measured by mean cortical thickness (table 2).  
 
Table 1: demographics and group comparisons 
  APOE e4 groups FH groups 
 Whole 
cohort 
[n=162] 
APOE e4+ 
[n=61] 
APOE e4- 
[n=101] 
Group 
difference 
Sig. FH+ [n=74] FH- 
[n=88] 
Group 
difference 
Sig. 
Age mean 
(SD) 
51.8 (+/- 
5.5) 
51.0 (+/- 
5.5) 
52.4 (+/- 
5.5) 
MWU= 
2585.5 
Z= -1.7 
 
.087 52.7 (+/- 
4.5) 
51.2 (+/- 
6.1) 
MWU= 
2889.5  
Z= -1.2 
 
.218 
Gender 
(m= male 
f= female) 
m= 44 
f= 118 
m= 17 
f= 44 
m= 27 
f= 74 
X2= 0.03 
df1 
 
.875 m=18 
f=56 
m=26 
f=62 
X2= 0.55 
 
.457 
APOE e4 
carrier 
status 
pos= 61 
neg= 101 
NA NA NA NA pos= 33 
neg= 41 
pos=28 
neg= 60 
X2= 2.80 
 
.095 
Years of 
education 
mean (SD) 
16.0 (+/- 
3.5) 
16.4 (+/- 
3.2) 
15.8 (+/- 
3.6) 
MWU= 
2771.5 
Z= -1.1 
 
.283 15.9 (+/- 
3.1) 
16.2 (+/- 
3.8) 
MWU= 
3092 
Z= -0.6 
.579 
Parental 
dementia 
pos= 74 
neg= 88 
pos= 33 
neg= 28 
pos= 41 
neg= 60 
X2= 2.80 
df1 
 
.095 NA NA NA NA 
18-point 
DRS mean 
(SD) 
5.7 (+/- 
2.9) 
6.7 (+/- 
2.5) 
5.2 (+/- 
2.9)  
MWU= 
2046 
Z= -3.6  
<.001** 6.5 (+/- 2.5) 5.1 (+/- 
3.0) 
MWU= 
2349 
Z= -3.1 
.002** 
15-point 
DRS mean 
(SD) 
4.5 (+/- 
2.4) 
4.2 (+/- 
2.2) 
4.6 (+/- 
2.6) 
MWU= 
2804.5 
Z=-1.0 
.332 5.0 (+/- 2.2) 4.0 (+/- 
2.6) 
MWU= 
2525 
Z= -2.5 
.013* 
Cognitive test scores (only significant findings) 
Narrative 
recall mean 
(SD) 
NA 28.1 (+/- 
7.6) 
25.0 (+/- 
8.3) 
MWU= 
2443 Z= -
2.2 
p=0.027* - - nil NA 
DRS = dementia risk score (18-point score includes APOE e4, 15-point score does not take APOE e4 into 
account); MWU=Mann-Whitney U; X2=Chi-squared; *p<.05, **p<.01 
 
 
Table 2: mean cortical thickness 
  APOE e4 groups FH groups 
 Whole 
cohort 
[n=162] 
APOE e4+ 
[n=61] 
APOE e4- 
[n=101] 
Group 
difference 
(sig) 
FH+ [n=74] FH- [n=88] Group 
difference 
(sig) 
Mean cortical 
thickness in mm 
(SD)  
2.46 (.07) 2.46 (.07) 2.45 (.06) t= -.37 
(p=.72) 
2.46 (.06) 2.46 (.08) t= .46 
(p=.65) 
 
 
Parental dementia diagnoses: 
74 participants reported at least 1 parent with a dementia diagnosis; of these 7 participants 
(9.5%) reported 2 parents with a dementia diagnosis. Of all the parental diagnoses (n=81) the 
breakdown was: 70.4% Alzheimer’s disease or mixed (Alzheimer’s and vascular) dementia, 
17.3% vascular dementia, 2.5% Frontotemporal dementia, 1.2% dementia with Lewy bodies, 
1.2% Parkinson’s disease dementia, (4.9% “unknown”). 
 
APOE e4 group comparisons: 
Significant clusters of increased CBF were found in the APOE e4+ group in left and right 
hemispheres compared to the APOE e4- group with correction for age, gender, years of 
education and multiple comparisons (FWE) (figure 2). The largest effects were seen in the 
left cingulate and left lateral frontal and parietal regions.  
 
 
Figure 2: Areas with significant increased cerebral blood flow in APOE e4 + vs - when 
corrected for age, gender and years of education. Scale shows TFCE clusters with FWE-
corrected significance levels between p=.01 and p=.05. 
FH group comparisons: 
Significant clusters of increased CBF were found in left and right hemispheres in the FH+ 
group compared to the FH- group with correction for age, gender, years of education and 
multiple comparisons (FWE) (figure 3). The distribution and extent of these clusters were 
similar to those seen in the APOE group comparison but the largest effects were seen in the 
left lateral temporoparietal region and left temporal pole. When additional correction for 
APOE status was applied this region of hyperperfusion persisted but the effect size was 
reduced (figure 4). 
 
 
Figure 3: Areas with significant increased cerebral blood flow in FH+ vs FH- group when 
corrected for age, gender and years of education. Scale shows TFCE clusters with FWE-
corrected significance levels between p=.01 and p=.05 
 
 
Figure 4: Areas with significant increased cerebral blood flow in FH+ vs FH- group with 
additional correction for APOE status (also corrected for age, gender and years of 
education). Scale shows TFCE clusters with FWE-corrected significance levels between 
p=.01 and p=.05 
 
Correlations: 
No significant correlations were found between CBF and age, years of education, DRS or 
cognitive test scores. 
 
 
  
DISCUSSION: 
As hypothesised, we found differences in regional cerebral perfusion between cognitively 
normal individuals in mid-life at higher and lower risk of AD. We found differences in 
regional brain perfusion between APOE e4+ and APOE e4- groups and FH+ and FH- groups 
when corrected for age, gender, years of education and multiple comparisons (FWE). 
Individuals in the PREVENT-Dementia cohort are of normal cognition and in mid-life. We 
did not find any group difference in mean cortical thickness between groups and the only 
significant group difference in terms of cognitive scores was in the narrative recall task where 
the APOE e4+ group scored slightly better than the APOE e4- group. Therefore, differences 
in perfusion are seen in the absence of gross structural brain changes, clinical disease or of 
prodromal (i.e. symptomatic) disease state. When additional correction for APOE status was 
applied to the FH group comparison the effect size of the group difference was much 
reduced, suggesting that hyperperfusion in this group may largely, but not exclusively, be 
driven by the effects of APOE e4. We found no significant difference in DRS between APOE 
e4+ and APOE e4- groups when APOE status was not included in the calculation and no 
correlation between regional CBF and DRS across all participants. These findings suggest 
that cardiovascular risk factors are not driving the difference in regional CBF between APOE 
e4 + and – groups. 
 
We found higher CBF in the APOE e4+ group in widespread areas; with the largest effect 
sizes seen in the left cingulate cortex and left lateral frontal and parietal regions. The 
cingulate is an area where early changes are seen in AD; reduced perfusion in the precuneus 
and posterior cingulate cortex are the most commonly reported findings in ASL MRI studies 
of AD[27]. Reduced perfusion of the posterior cingulate predicts conversion from MCI to 
AD[28]. In contrast we found increased perfusion in the posterior and anterior cingulate in 
the APOE e4+ group. We also found marked hyperperfusion in left frontal and parietal 
regions in the APOE e4+ group; we did not find previous studies which reported this finding, 
though intriguingly, hypoperfusion in parietal and frontal regions has been widely reported in 
MCI, AD and to a lesser extent in cognitively-normal older adults[12,29].  
 
Carrying an APOE e4 allele is known to increase the risk of developing AD and to lower the 
age of onset of cognitive decline. APOE e4 is involved in cerebrovascular function and is 
associated with a range of vascular conditions including arteriosclerosis and amyloid 
angiopathy[30]. It is generally accepted that hippocampal atrophy with a relative lack of 
whole brain atrophy is associated with APOE e4[31], however, the relationship between brain 
perfusion and APOE status is not as clear. Previous studies suggest that the effect of APOE 
may be modified by other factors such as age or disease severity. For example, Kobayashi et 
al.[32] found an impact of APOE e4 on CBF in those with moderate AD but not mild or 
severe disease while Wierenga et al.[10] found that APOE e4+ individuals demonstrated 
relatively increased anterior cingulate perfusion in young adulthood and relatively decreased 
anterior cingulate perfusion in old age. It may be that increased cerebral blood flow in APOE 
e4 carriers contributes to the pathogenesis of the disease in its early stages, for example, by 
aiding the seeding of tau and amyloid, accelerating the degenerative process. Increased neural 
connectivity which is related to increased cerebral perfusion has been found to be associated 
with higher tau and amyloid burden in AD[33]. Alternatively it may be that hyperperfusion 
prior to the onset of clinical symptoms reflects some sort of ‘compensatory’ mechanism, i.e. 
supporting normal cognitive function in brains at early stages of neurodegeneration, as 
suggested for example by Ding et al.[29]. In support of this theory are the findings of Zlatar 
et al.[34] who found a relationship between increased CBF and poorer verbal memory in 
cognitively-normal APOE e4 carriers. In our cohort we did not find any correlation between 
CBF and cognitive test scores; the only group difference in cognitive performance was in the 
narrative recall task in which the APOE e4+ group (who had areas of increased regional 
CBF) performed slightly better than the APOE e4- group.  
 
In their reviews Wierenga et al.[30] and Zhang et al.[35] discussed the implications of 
previous ‘paradoxical’ findings of both relative cerebral hypo- and hyperperfusion in ‘at risk’ 
individuals, which appear to be related to how the relationship between CBF and risk factors 
(e.g. vascular or genetic) is modified by age. Zhang et al. describe a pattern in which, 
following a peak in early adulthood, CBF gradually declines with age but is modified by 
lifestyle and risk factors; in APOE e4 carriers a second peak is described in middle-age[35], 
followed by a decline sharper than that of non-carriers as the individual moves into older age. 
The capillary dysfunction model of AD provides an explanatory framework for such a 
pattern. Østergaard et al.[36] describe an evolving relationship between regional CBF, 
capillary permeability, capillary surface area, and capillary transit time heterogeneity. 
According to this model, the neurovascular changes that accompany AD (e.g. increasing 
blood vessel tortuosity) predict that an increase in CBF would be seen in pre-symptomatic 
AD; switching to a decrease in CBF part way through the subclinical phase and markedly 
decreasing as dementia progresses. According to this theory our findings of regional 
hyperperfusion in those at high risk of AD could reflect a very early marker of neural and 
vascular dysfunction. 
 
An alternative explanation for areas of relative hyperperfusion in the APOE e4+ group is that 
in younger age the APOE e4 allele confers (or is related to) beneficial effects on brain 
function and memory. For example, Mondadori et al.[37] found that some aspects of 
cognition were better in young, healthy APOE e4 carriers. This theory would not be 
supported by the common finding that lower educational attainment is associated with AD; 
although this association has not been found universally and many individual and social 
factors influence educational attainment aside from innate cognitive ability[38]. In our cohort 
minimal group differences were seen in terms of cognitive test results; there was no 
difference in cognitive test results between the FH groups but the APOE e4+ group 
performed slightly better in the narrative recall task. We did not find a correlation between 
individual regional CBF and cognitive test results, therefore our findings would not support 
the theory that APOE e4 has a beneficial effect on some aspects of cognitive function via an 
increase in regional cerebral perfusion. 
 
We found that regional hyperperfusion was more widespread when we defined the groups by 
APOE status rather than FH. When we included APOE status as an additional covariate the 
group difference between FH + and - was much reduced, however some areas of 
hyperperfusion in left temporal, parietal and frontal regions persisted. This implies that these 
effects on perfusion are not being driven by APOE e4 alone and that some familial or 
environmental risk factor aside from APOE e4 is playing a role. The greatest effect size was 
seen in the left lateral temporal region in the FH+ group and in left cingulate and left lateral 
frontal and parietal regions in the APOE e4+ group. The regional patterns of hyperperfusion 
are similar but not identical; it may be that pathologies in different brain regions or in 
different individuals will ultimately be explained by different causative mechanisms. APOE 
e4 is not the only genetic variant known to be associated with sporadic AD risk; thousands of 
common genetic variants which increase dementia risk have been identified via genome-wide 
association studies (GWAS)[39]. There is emerging evidence that these variants may 
contribute to AD risk via changes to vasculature[11]. The significant difference in DRS 
between FH+ and FH- groups (which is not accounted for by APOE status) suggests that the 
additional risk conferred by FH may be bestowed via increased cardiovascular risk. 
 
Strengths and limitations: 
A major strength of our study is the number of participants and the richness of the data 
collected; a review of the literature revealed few studies of comparable size. The data 
reported here is pilot baseline data; the data will continue to grow richer as further baseline 
and follow-up data becomes available over the next 3 years. Neurodegenerative dementias 
such as AD develop over the years and decades prior to the onset of clinically significant 
symptoms, therefore large, longitudinal cohorts like the PREVENT-Dementia cohort are 
invaluable; ultimately allowing us to describe how brains change structurally and functionally 
as individuals move through middle to older-age, with a proportion going on to develop MCI 
and dementia. 
 
In the PREVENT-Dementia study dementia risk is defined using FH and APOE e4. The  
causes of AD are multifactorial including both genetic and lifestyle factors[39,40]; 
genotyping in the study is limited to APOE analysis, therefore, we cannot explore the effects 
of broader genetic risk and the relationship between this risk and CBF. 
 
The group difference in CBF between FH groups was largely explained by APOE e4. 
Although the parental dementia diagnoses were primarily reported to be AD or mixed AD 
and vascular (70.4%), our sample contains parental dementia diagnoses other than AD (such 
as vascular dementia and Frontotemporal dementia). Parental dementia subtype is a self-
reported measure within the cohort and due to participant reporting errors or diagnostic 
uncertainty, the cohort may be more (or less) heterogenous than reported. It may be therefore, 
that the effect of FH would become more marked in a larger (or more homogenous) cohort.  
 
Conclusions: 
We found areas of regional cerebral hyperperfusion in APOE e4+ compared to APOE e4- 
when corrected for age, gender, years of education and FWE. Our findings broadly contrast 
with those reported in studies of individuals with MCI and AD but align somewhat with 
previous literature concerning younger cognitively normal individuals at high risk of 
developing dementia. The significance of such findings is not yet clear and different theories 
could be proposed to account for them. In this paper we have postulated that hyperperfusion 
in high risk individuals may contribute to the pathogenesis of AD, may reflect a  
‘compensatory’ mechanism (in which the brain is working ‘harder’ to compensate for early 
neural damage), or may be a marker of early neural ‘dysfunction’ in individuals who are 
likely to develop AD. Further longitudinal data, including even earlier imaging, is indicated 
to determine at what point before dementia onset perfusion increases and will help us to 
understand its origins and implications. Examination of the full PREVENT-Dementia cohort 
and longitudinal follow-up of this cohort will address the limitations of this analysis.  
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